S22-455 Muscle-specific Base Editor Enables Correction of Pathogenic Mutations in vivo for Dilated Cardiomyopathy Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes. Lars Steinmetz Markus Grosch